Open AccessUse of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations
Author(s) -
Daniel Kirchhoff,
Murata Kazunori,
Katie L. Thoren
Publication year - 2021
Publication title -
the journal of applied laboratory medicine
Language(s) - English
Resource type - Journals
eISSN - 2576-9456
pISSN - 2475-7241
DOI - 10.1093/jalm/jfab055
Subject(s) - daratumumab , immunofixation , medicine , clone (java method) , serum protein electrophoresis , oncology , monoclonal , multiple myeloma , monoclonal antibody , immunology , chemistry , antibody , dna , biochemistry , lenalidomide
The incorporation of monoclonal antibodies, such as daratumumab, into multiple myeloma treatment regimens has led to the issue of false-positive interference in both serum protein electrophoresis (SPEP) and immunofixation (IF). The Hydrashift assay removes daratumumab interference from IF, allowing for correct interpretation. Here, we retrospectively examined the use of the Hydrashift assay at a large cancer center and provide guidelines on its most appropriate use.